Patients in insulin analogues use via judicial litigation: poor glycemic control and incorrect use

Thays Santos Mendonça; William Neves Oliveira; Vinícius Silva Belo; Eduardo Sérgio Silva; Mariana Linhares Pereira; Paulo Roque Obreli-Neto; Liliana Aparecida Oliveira Silva; Silvio Barberato-Filho; Lívia Luize Marengo; André Oliveira Baldoni

doi:10.1590/s2175-97902025e24526

Authors

Thays Santos Mendonça Postgraduate Program in Health Sciences, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu, (CCO), Divinópolis, Minas Gerais, Brazil
William Neves Oliveira Postgraduate Program in Health Sciences, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu, (CCO), Divinópolis, Minas Gerais, Brazil
Vinícius Silva Belo Postgraduate Program in Health Sciences, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu, (CCO), Divinópolis, Minas Gerais, Brazil
Eduardo Sérgio Silva Postgraduate Program in Health Sciences, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu, (CCO), Divinópolis, Minas Gerais, Brazil
Mariana Linhares Pereira Postgraduate Program in Pharmaceutical Sciences, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu (CCO), Divinópolis, Minas Gerais, Brazil
Paulo Roque Obreli-Neto Pharmacy Department, University Center of the Integrated Colleges of Ourinhos (UniFIO), Ourinhos, São Paulo, Brazil
Liliana Aparecida Oliveira Silva Municipal Health Department of Divinópolis, Minas Gerais, Brazil
Silvio Barberato-Filho Graduate Program in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, São Paulo, Brazil
Lívia Luize Marengo Graduate Program in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, São Paulo, Brazil
André Oliveira Baldoni Postgraduate Program in Pharmaceutical Sciences, Federal University of São João Del-Rei (UFSJ), Campus Centro-Oeste Dona Lindu (CCO), Divinópolis, Minas Gerais, Brazil

DOI:

https://doi.org/10.1590/s2175-97902025e24526

Keywords:

Diabetes mellitus type 1, Drug utilization, Economics, pharmaceutical, Health judicialization, Insulin, Right to health

Abstract

The aim of this study is to analyze the glycemic control of patients with type 1 diabetes mellitus (T1DM) in insulin analogues use through judicial litigation in the Public Health System. A crosssectional study was conducted with patients who have T1DM and acquire insulin analogues through judicial litigation in a Brazilian city. The patients who agreed to participate underwent laboratory tests of fasting blood glucose and glycated hemoglobin (HbA1c) and answered validated questionnaires about attitudes and skills towards the insulin application. The female gender predominated (n=22; 53.7 %) with a mean age of 32.3 ± 13.0 years. The average fasting blood glucose and HbA1c levels were 175.2 ± 67.8 mg/dL and 8.7 ± 1.7%, respectively. The monthly expenses on insulin for these patients was US$47.4 ± 28.4. Considering the HbA1c levels, the vast majority of patients did not have glycemic control of the disease (90.2 %) and most did not perform the correct insulin application technique (73.7 %). The use of more expensive insulins and the expense of more financial resources were not associated with better glycemic control of T1DM patients.

Downloads

Download data is not yet available.

References

Aghili R, Polonsky WH, Valojerdi AE, Malek M, Keshtkar AA, Esteghamati A, et al. Type 2 Diabetes: Model of Factors Associated with Glycemic Control. Can J Diabetes. 2016;40:424–430. doi:10.1016/j.jcjd.2016.02.014.

American Diabetes Association [ADA] ADA: Standards of Care in Diabetes. v. 47, s. 1. American Diabetes Association, 2024.

Batista JMF, Becker TAC, Zanetti ML, Teixeira CRDS. O ensino em grupo do processo de aplicação de insulina. Rev Eletrônica Enferm. 2013;15:71–79. doi:10.5216/ree.v15i1.16179.

Beran D, Hemmingsen B, Yudkin JS. Analogue insulin as an essential medicine: the need for more evidence and lower prices. Lancet Diabetes Endocrinol. 2019;7:338. doi:10.1016/S2213-8587(19)30111-1.

Bernardinis N, Gubert VT, Ferreira CM, Barreto JOM. Healthcare judicialization: an analysis of indicators and official data on medications. Rev Bras Enferm. 2024; 77(3). doi: 10.1590/0034-7167-2022-0413.

Black JE, Harris SB, Ryan BL, Zou G, Ratzki-Leewing A. Real-world effects of second-generation versus earlier intermediate/basal insulin analogues on rates of hypoglycemia in adults with type 1 and 2 diabetes (iNPHORM, US). Diabetes Ther. 2023; 14:1299-1317. doi: 10.1007/s13300-023-01423-3.

Camargos AMT, Gonçalves ACO, Cazarim MS, Sanches C, Pereira LRL, Baldoni AO. Patients lacking glycemic control place more burdens on health services with the use of medications. Diabetes Metab Syndr Clin Res Rev. 2018;12:279–283. doi:10.1016/j.dsx.2017.12.010.

Chieffi AL, Barradas RDCB, Golbaum M. Legal access to medications: A threat to Brazil's public health system? BMC Health Serv Res. 2017;17:1–12. doi:10.1186/s12913-017-2430-x.

Cobas RA, Bosi MF, Mattos ASM, Monteiro LRT, Negrato CA, Araujo LA, et al. The cost of type 1 diabetes: A nationwide multicentre study in Brazil. Bull. World Health Organ. 2013;91: 434–440. doi:10.2471/BLT.12.110387.

Conselho Federal de Farmácia. Grupo de trabalho de farmacêuticos no sistema de justiça. Judicialização de medicamentos: apoio técnico-farmacêutico para a diminuição e/ou qualificação das demandas. Brasília, 2018.

Dias LLDS, Santos MAB, Osorio-de-Castro CGS. Public financing of human insulins in Brazil: 2009-2017. Rev Bras Epidemiol. 2020;23:e200075. doi:10.1590/1980-549720200075.

Flora MC, Gameiro MGH. Dificuldades no autocuidado dos adolescentes com daibetes mellitus tipo 1. Rev Enferm Ref. 2016:31–40. Available at: http://repositorio.esenfc.pt/?url=ZihBVhr4.

Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018. doi:10.1002/14651858.CD013228.

Gentile S, Strollo F, Ceriello A. Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear? Diabetes Ther. 2016;7:401–409. doi:10.1007/s13300-016-0187-6.

Instituto Brasileiro de Geografia e Estatística (IBGE). IBGE Cidades. Available at: https://cidades.ibge.gov.br/brasil/mg/divinopolis/panorama. Accessed in 22/10/2024.

International Diabetes Federation [IDF]. Diabetes Atlas, 8th Edn. Brussels, Belgium: International Diabetes Federation, 2017.

International Diabetes Federation (IDF) Diabetes Atlas, 9th Edn. Brussels, Belgium: International Diabetes Federation, 2019.

International Diabetes Federation (IDF). Diabetes Atlas, 10th Edn. Brussels, Belgium: International Diabetes Federation, 2021.

Lau E, Salem A, Chan JCN, So WY, Kong A, Lamotte M, et al. Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: A cost-effectiveness analysis. Cost Eff Resour Alloc. 2019;17:1–13. doi:10.1186/s12962-019-0180-9.

Lee TY, Kuo S, Yang CY, Ou HT. Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: a population-based cohort followed over 10 years. Br J Clin Pharmacol. 2020; 86:852-860. doi: 10.1111/bcp.14188.

Melo KFS, Bahia LR, Pasinato B, Porfirio GJM, Martimbianco AL, Riera R, et al. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: A systematic review and meta-analysis. Diabetol Metab Syndr. 2019;11:1–13. doi:10.1186/s13098-018-0397-3.

Mendonça TS, Silva ES, Pereira ML, Obreli-Neto PR, Belo VS, Ferreira GC, et al. Use of more expensive insulin despite guidelines in Brazil. Diabetes Metab Syndr Clin Res Rev. 2020;14:155–157. doi:10.1016/j.dsx.2020.02.005.

Neugebauer R, Schroeder EB, Reynolds K, Schmittdiel JA, Loes L, Dyer W. Comparison of mortality and major cardiovascular events among adults with type 2 diabetes using human vs analogue insulins. Jama Network Open. 2020; 3:1. Doi: 10.1001/jamanetworkopen.2019.18554.

Pamungkas RA, Chamroonsawasdi K, Vatanasomboon P. A systematic review: Family support integrated with diabetes self-management among uncontrolled type II diabetes mellitus patients. Behav Sci (Basel). 2017;7:1–17. doi:10.3390/bs7030062.

Peres HA, Leira Pereira LR, Martinez EZ, Viana CM., Freitas MCF. Elucidating factors associated with non-adherence among Type 1 diabetes patients in primary care setting in Southeastern Brazil. Prim Care Diabetes. 2020;14:85–92. doi:10.1016/j.pcd.2019.06.002.

Peres HA, Martinez EZ, Viana CM, Pereira LRL. Glycemic control and associated factors in patients with type 1 diabetes mellitus in primary care in Southeastern Brazil. Braz J Pharm Sci. 2022; 58. doi: /10.1590/s2175-97902022e20985.

Pirić M, Šojat D, Mišković V, Šapina M, Popović Z, Bačun T. Glycaemia, renal function and body mass in men and women with type 2 diabetes. Med Glas. 2020;17:496–502. doi:10.17392/1210-20.

Pinheiro P, Garcia J, Cardoso E, Luz D, Silva V. Farmacoeconomia: gastos com análogos de insulina adquiridos por meio de judicialização em um município do estado do Pará, Brasil, no ano de 2016. J Bras Econ da Saúde. 2019;11:42–48. doi:10.21115/jbes.v11.n1.p42-8.

Reis P, Marcon SS, Teston EF, Nass EMA, Ruiz AGB, Francisqueti V, et al. Educational intervention on insulin knowledge and management at home. Acta Paul Enferm. 2020; 33:1-9. doi: 10.37689/actaape/2020AO0241.

Rodrigues FFL. Conhecimento e atitudes de usuários com diabetes mellitus em uma Unidade Básica Distrital de Saúde de Ribeirão Preto-SP. Universidade de São Paulo. 2011:120.

Sant'Ana JMB, Pepe VLE, Osorio-De-Castro CGS, Ventura M. Essencialidade e assistência farmacêutica: Considerações sobre o acesso a medicamentos mediante ações judiciais no Brasil. Rev Panam Salud Publica/Pan Am J Public Heal. 2011;29:138–144. doi:10.1590/S1020-49892011000200010.

Santos WP. Preparo e administração de insulina entre usuários com diabetes mellitus. [dissertação]. Paraíba: Universidade Federal da Paraíba; 2020.

Saraiva RSP. Distribution policies of insulinic comsuptions and medicines in the single health system. J. Diabetes Endocrinol Res. 2023; 4(1): 1-8. doi: 10.47485/2693-2458/1026.

Secretaria de Estado de Saúde de Minas Gerais. Relação de Medicamentos do Componente Especializado da Assistência Farmacêutica (CEAF) disponibilizados pela SES-MG. Available at: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.saude.mg.gov.br/images/documentos/LISTA%20DE%20MEDICAMENTOS%20DO%20CEAF%2031-10-2024.pdf. Accessed in 05/11/2024.

Shafie AA, Ng CH. Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia. Clin Outcomes Res. 2020;12:333–343. doi:10.2147/ceor.s244884.

Silva RE, Lima EC, Novaes MRCG, Osorio-de-Castro CGS. The High "Cost" of Experimental Drugs Obtained Through Health Litigation in Brazil. Front Pharmacol. 2020;11: 1–7. doi:10.3389/fphar.2020.00752.

Sociedade Brasileira de Diabetes [SBD] Recomendações sobre o tratamento injetável do diabetes: Insulinas e Incretinas. Soc Bras Diabetes. 32, 2017.

Sociedade Brasileira de Diabetes [SBD]. Dados epidemiológicos do diabetes mellitus no Brasil. Soc Bras Diabetes, 2023.

Stacciarini TSG, Caetano TSG, Pace AE. Dose de insulina prescrita versus dose de insulina aspirada. ACTA Paul Enferm. 2011;24:789–793. doi:10.1590/S0103-21002011000600010.

Stacciarini TSG, Haas VJ, Pace AE. Fatores associados à auto-aplicação da insulina nos usuários com diabetes mellitus acompanhados pela Estratégia Saúde da Família. Cad Saude Pública. 2008; 24:1314–1322. doi:10.1590/S0102-311X2008000600012.

Tonaco LAB, Velasquez-Melendez G, Moreira AD, Andrade FCD, Malta DC, Felisbino-Mendes MS. Awareness of the diagnosis, treatment and control of diabetes mellitus in Brazil. Rev Saúde Pública. 2023; 57:75. Doi:10.11606/s1518-8787.2023057005167.

Torres HC, Hortale VA, Schall VT. Validação dos questionários de conhecimento (DKN-A) e atitude (ATT-19) de Diabetes Mellitus. Rev Saude Pública. 2005;39:906–911. doi:10.1590/S0034-89102005000600006.

Vianna MS, Silva PAB, Nascimento CV, Soares SM. Competência para o autocuidado na administração de insulina por idosos septuagenários ou mais de idade. Rev Lat Am Enfermagem. 2017:25. doi:10.1590/1518-8345.2080.2943.

Wisgerhof W, Ruijgrok C, Den Braver NR, Borgonjen-van Den Berg KJ, Van Der Heijden AAWA, Elders PJM, et al. Phenotypic and lifestyle determinants of HbA1c in the general population – the Hoorn study. PLoS One. 2020;15:1–11. doi:10.1371/journal.pone.0233769.

Yamauti SM, Otavio J, Barreto M, Barberato-filho S. strategies implemented by public institutions to approach the judicialization of health care in Brazil: A systematic scoping review. Front Pharmacol. 2020;11:1–18. doi:10.3389/fphar.2020.01128.

Patients in insulin analogues use via judicial litigation: poor glycemic control and incorrect use

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

Data Availability Statement

Issue

Section

License

How to Cite

Funding data